TG Therapeutics commences TGR-1202 Phase I trial
TG Therapeutics has begun first-in-human, Phase I trial of TGR-1202 in patients suffering from hematologic malignancies such as relapsed or refractory Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Peripheral T-Cell Lymphoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Hematology | Leukemia | Lymphoma | Non-Hodgkin's Lymphoma | Pharmaceuticals | T-cell Lymphoma